Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

59.82
+0.38000.64%
Post-market: 59.860.0400+0.07%19:55 EST
Volume:9.71M
Turnover:581.18M
Market Cap:121.39B
PE:-13.55
High:60.26
Open:59.43
Low:59.38
Close:59.44
Loading ...

Company Profile

Company Name:
Bristol-Myers Squibb
Exchange:
NYSE
Establishment Date:
1887
Employees:
34100
Office Location:
Route 206 & Province Line Road,Princeton,New Jersey,United States
Zip Code:
08543
Fax:
- -
Introduction:
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Directors

Name
Position
Christopher Boerner
Chair of the Board and Chief Executive Officer
Deepak L. Bhatt
Director
Derica W. Rice
Director
Karen H. Vousden
Director
Manuel Hidalgo Medina
Director
Michael R. McMullen
Director
Paula A. Price
Director
Peter J. Arduini
Director
Phyllis R. Yale
Director
Theodore R. Samuels
Director

Shareholders

Name
Position
Christopher Boerner
Chair of the Board and Chief Executive Officer
David V. Elkins
Executive Vice President and Chief Financial Officer
Phil Holzer
Senior Vice President and Controller
Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer
Amanda Poole
Executive Vice President, Chief People Officer
Benjamin Hickey
President,RayzeBio Organization
Cari Gallman
Executive Vice President, Corporate Affairs
Greg Meyers
Executive Vice President, Chief Digital and Technology Officer
Karin Shanahan
Executive Vice President, Global Product Development & Supply
Lynelle Hoch
President, Cell Therapy Organization
Robert Plenge
Executive Vice President, Chief Research Officer, Head of Research
Samit Hirawat
Executive Vice President, Chief Medical Officer
Sandra Leung
Executive Vice President, General Counsel